Clindamycin Hydrochloride and Sodium Chloride Injection

This product belongs to the lincomycin antibiotics, which is a derivative of lincomycin. Its antibacterial spectrum is the same as that of lincomycin, and its antibacterial activity is 4-8 times stronger than that of lincomycin. It has high antibacterial activity against Gram-positive anaerobic bacteria such as Staphylococcus (including penicillin-resistant strains), Streptococcus, Corynebacterium diphtheriae, Bacillus anthracis, etc. It also has good antibacterial activity against Gram-negative anaerobic bacteria. Bacteroides including Haemophilus influenzae, Neisseria and Mycoplasma are all resistant to this product. There is no cross-resistance between this product and penicillin, chloramphenicol, cephalosporins and tetracyclines, but it has partial cross-resistance with macrolides and complete cross-resistance with lincomycin. The mechanism of action of this product is to bind to the 50S subunit of the bacterial ribosome, prevent the extension of the peptide chain, and thus inhibit the protein synthesis of bacterial cells.

The main ingredients of this product are clindamycin hydrochloride and sodium chloride, and its active ingredient is clindamycin hydrochloride. Its chemical name is 6-(1-methyl-trans-4-propyl-L-2-pyrrolidinecarboxamido)-1-thio-7(S)-chloro-6,7,8-trideoxy-L-threo-α-D-galacto-octinopyranoside hydrochloride. The chemical structure is: Molecular formula: C18H33ClN2O5S·HCl Molecular weight: 461.44 Excipients: sodium chloride

This product is a colorless or almost colorless clear liquid.

1. For the treatment of the following infectious diseases caused by Gram-positive bacteria: (1) tonsillitis, suppurative otitis media, sinusitis, etc.; (2) acute bronchitis, acute exacerbation of chronic bronchitis, pneumonia, lung abscess and bronchiectasis combined infection, etc.; (3) skin and soft tissue infections: furuncle, carbuncle, abscess, fossa inflammation, trauma and postoperative infection, etc.; (4) urinary tract infections: acute urethritis, acute pyelonephritis, prostatitis, etc.; (5) others: osteomyelitis, sepsis, peritonitis and oral infection, etc.; 2. For the treatment of various infectious diseases caused by anaerobic bacteria: (1) empyema, lung abscess, anaerobic lung disease; (2) skin and soft tissue infections, sepsis; (3) intra-abdominal infections: peritonitis, intra-abdominal abscess; (4) female pelvic and genital infections: endometritis, non-gonococcal fallopian tube and ovarian abscess, pelvic fossa inflammation and post-gynecological surgery infection, etc.

Intravenous drip. Each drip time should be no less than 30 minutes. Adults: 0.6-1.2 g per day, divided into 2-4 times; severe infection: 1.2-2.4 g per day, divided into 2-4 times. Children 4 weeks and older: 15-25 mg/kg per day, divided into 3-4 times; severe infection: 25-40 mg/kg, divided into 3-4 times. The intravenous administration speed should not be too fast, and the amount of drug infused within 1 hour should not exceed 1200 mg.

1. Gastrointestinal reactions: Occasionally nausea, vomiting, abdominal pain and diarrhea; severe cases may include abdominal colic, abdominal tenderness, and severe diarrhea (watery or purulent). Accompanied by fever, abnormal thirst and fatigue (pseudomembranous colitis). Diarrhea. Enteritis and pseudomembranous colitis may occur in the early stages of medication or several weeks after discontinuation of medication. 2. Blood system: Occasionally leukopenia, neutropenia, eosinophilia and thrombocytopenia may occur. 3. Allergic reactions: Rashes, itching, etc., occasionally urticaria, angioedema and serum sickness reactions may occur. Exfoliative dermatitis, bullous dermatitis, erythema multiforme and Steven-Johnson syndrome are rare. 4. Abnormal liver and kidney function, such as elevated serum aminotransferase, jaundice, etc. 5. Intravenous infusion may cause phlebitis. 6. Others: tinnitus, dizziness, candidal infection, etc.

Patients with a history of allergy to clindamycin or lincomycin are contraindicated.

Precautions for children: This product is contraindicated for infants under 4 weeks of age. Other children should pay attention to the function of their vital organs when taking this product. Precautions for pregnancy and lactation: 1. Animal experiments show that this product has no effect on the fetus, but there is still a lack of experience in its use in pregnant women. And this product can pass through the placenta, so pregnant women should use it with caution. 2. This product can be secreted into breast milk. Therefore, lactating women should use it with caution and stop breastfeeding when using this product. Precautions for the elderly: Elderly people with serious underlying diseases are prone to adverse reactions such as diarrhea or pseudomembranous colitis, and need to be closely observed when taking the drug.

1. This product can enhance the neuromuscular blockade of inhaled anesthetics, leading to skeletal muscle weakness and respiratory resistance or paralysis (apnea). Caution should be taken when used in combination during or after surgery. Treatment with anticholinesterase drugs or calcium salts is expected to be effective. 2. This product can be used in combination with antiperistaltic antidiarrheal drugs and antidiarrheal drugs containing white clay. It may cause pseudomembranous colitis with severe watery diarrhea during the course of treatment or even a few weeks after the course of treatment. Because it can delay the excretion of colonic endotoxins, thereby causing prolonged and aggravated diarrhea, this product should not be used in combination with antiperistaltic antidiarrheal drugs. When used in combination with antidiarrheal drugs containing white clay, the absorption of this product will be significantly reduced. Therefore, the two should not be used at the same time and a certain interval (at least 2 hours) is required. 3. This product has a neuromuscular blocking effect and can enhance the effect of neuromuscular blocking drugs. The two should be avoided in combination. When this product is used in combination with anti-myasthenic drugs, the latter will weaken the effect on skeletal muscles. In order to control the symptoms of myasthenia gravis, the dose of anti-myasthenic drugs should be adjusted when used in combination. 4. Chloramphenicol or erythromycin can replace this product at the target site, or inhibit the binding of this product to the bacterial ribosome 50S subunit. In vitro tests show that this product has an antagonistic effect with erythromycin, so this product should not be used in combination with chloramphenicol or erythromycin. 5. When used in combination with opioid analgesics, the respiratory depression of this product and the central respiratory depression of opioids may add up to prolong respiratory depression or cause respiratory paralysis (apnea), so patients must be closely observed or monitored. 6. This product should not be added to infusions with complex components to avoid incompatibility.

Sealed, store in a cool place (not exceeding 20℃).

100ml: Clindamycin 0.3g and sodium chloride 0.85g

24 months

Zhejiang Guojing Pharmaceutical Co., Ltd.

• Founded in:

  1997-06-01

• Address:

  No. 9 Kelun Avenue, Lutian Industrial Park, Longquan City, Lishui City, Zhejiang Province

• Tax NO.:

  91331181148543087L

• Registered Funds:

  51.8 million yuan

• Email:

  Log in to view